Janssen’s Stelara May Be Medicare Price Negotiation Savings Star

New research is gauging how much savings CMS may see on the prices of the first 10 drugs selected for negotiation.

Will Stelara Be The 'Winner'? • Source: Shutterstock

Research replicating the process that the Centers for Medicare and Medicaid Services is using to set Medicare prices for 10 selected drugs suggests that Janssen Pharmaceuticals Inc.’s Stelara will yield the greatest level of savings, UC San Diego researcher and pharmacy professor Inmaculada Hernandez reported.

Key Takeaways

  • The Biden Administration may spotlight Stelara as the best example of how the Medicare negotiation program can lower prices, research sponsored by the Commonwealth Fund now pending publication suggests.

“I predict Stelara will be promoted this year as the main success of the negotiation process,” she said 6 May...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet